AlzeCure Pharma (ST:ALZCUR) — Stock Price
AlzeCure Pharma (ST:ALZCUR) is currently trading at Skr6.72 SEK, down 3.17% today. Over the past 52 weeks, shares have ranged between Skr1.34 and Skr7.66. This page tracks AlzeCure Pharma's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AlzeCure Pharma market capitalisation.
AlzeCure Pharma (ALZCUR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks AlzeCure Pharma's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
AlzeCure Pharma Income Statement — Revenue, Profit & Earnings by Year
AlzeCure Pharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Cost of Revenue | Skr293.00K | Skr476.00K | Skr570.00K | Skr576.00K | Skr495.00K |
| Gross Profit | Skr-293.00K | Skr-476.00K | Skr-570.00K | Skr-576.00K | Skr-495.00K |
| Research & Development | Skr24.69 Million | Skr27.23 Million | Skr46.18 Million | Skr66.72 Million | Skr62.36 Million |
| SG&A | Skr11.47 Million | Skr10.60 Million | Skr10.17 Million | Skr11.27 Million | Skr9.38 Million |
| Total Operating Expenses | Skr36.14 Million | Skr37.83 Million | Skr56.57 Million | Skr78.14 Million | Skr71.58 Million |
| Operating Income | Skr-36.45 Million | Skr-38.26 Million | Skr-56.44 Million | Skr-77.93 Million | Skr-71.58 Million |
| EBITDA | Skr-35.70 Million | Skr-37.87 Million | Skr-55.67 Million | Skr-77.20 Million | Skr-70.87 Million |
| EBIT | Skr-35.99 Million | Skr-38.34 Million | Skr-56.24 Million | Skr-77.78 Million | Skr-71.36 Million |
| Interest Expense | Skr19.00K | Skr7.00K | Skr4.00K | Skr1.00K | Skr1.00K |
| Income Before Tax | Skr-35.23 Million | Skr-37.17 Million | Skr-56.24 Million | Skr-77.78 Million | Skr-71.37 Million |
| Income Tax Expense | — | Skr-82.00K | Skr-203.00K | Skr1.00K | Skr1.00K |
| Net Income | Skr-35.23 Million | Skr-37.17 Million | Skr-56.04 Million | Skr-77.78 Million | Skr-71.37 Million |
AlzeCure Pharma Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes AlzeCure Pharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Skr34.44 Million | Skr32.00 Million | Skr70.84 Million | Skr45.65 Million | Skr117.83 Million |
| Total Current Assets | Skr34.21 Million | Skr31.61 Million | Skr27.50 Million | Skr44.20 Million | Skr115.86 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr2.71 Million | Skr2.51 Million | Skr1.93 Million | Skr2.46 Million | Skr3.42 Million |
| Inventory | — | Skr-2.51K | Skr-1.93K | Skr-2.46K | Skr-8.00K |
| Property, Plant & Equipment | Skr207.00K | Skr376.00K | Skr852.00K | Skr1.42 Million | Skr1.94 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr8.25 Million | Skr8.23 Million | Skr10.35 Million | Skr12.67 Million | Skr7.07 Million |
| Total Current Liabilities | Skr8.25 Million | Skr8.23 Million | Skr10.35 Million | Skr12.67 Million | Skr7.07 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Skr-31.50 Million | Skr-29.10 Million | Skr-25.58 Million | Skr-41.74 Million | Skr-112.43 Million |
| Total Stockholder Equity | Skr26.18 Million | Skr23.77 Million | Skr60.48 Million | Skr32.97 Million | Skr110.75 Million |
| Retained Earnings | Skr-375.45 Million | Skr-340.22 Million | Skr-303.05 Million | Skr-246.81 Million | Skr-169.03 Million |
AlzeCure Pharma Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how AlzeCure Pharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-35.12 Million | Skr3.06 Million | Skr-99.91 Million | Skr-70.64 Million | Skr-69.51 Million |
| Capital Expenditures | Skr124.00K | Skr0.00 | Skr0.00 | Skr54.00K | Skr671.00K |
| Free Cash Flow | Skr-35.25 Million | Skr3.06 Million | Skr-99.91 Million | Skr-70.69 Million | Skr-70.18 Million |
| Investing Cash Flow | Skr-124.00K | Skr7.00K | Skr0.00 | Skr-54.00K | Skr-671.00K |
| Financing Cash Flow | Skr37.65 Million | Skr459.00K | Skr83.75 Million | Skr83.75 Million | Skr114.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr293.00K | Skr476.00K | Skr570.00K | Skr576.00K | Skr495.00K |
| Change in Cash | Skr2.40 Million | Skr3.52 Million | Skr-16.16 Million | Skr-70.69 Million | Skr-70.06 Million |
AlzeCure Pharma Earnings History — EPS Actual vs. Analyst Estimates
Track AlzeCure Pharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 25, 2026 | — | — | — |
| Nov 11, 2025 | -0.09 | — | — |
| Aug 26, 2025 | -0.10 | — | — |
| May 05, 2025 | -0.11 | — | — |
| Feb 27, 2025 | -0.11 | — | — |
| Nov 11, 2024 | -0.08 | — | — |
| Aug 26, 2024 | -0.12 | — | — |
| Apr 25, 2024 | -0.15 | — | — |